Integra LifeSciences stockholders elect seven directors, approve equity plan increase
At its annual meeting on May 7, 2026, Integra LifeSciences stockholders elected all seven director nominees, ratified PricewaterhouseCoopers LLP as auditor for 2026, and approved the advisory executive compensation proposal. They also approved Amendment No. 3 to the equity incentive plan, which increases the shares available for awards under the plan by 3,550,000.
Key points
- Annual meeting held May 7, 2026; all seven director nominees elected to serve until the 2027 annual meeting.
- Plan Amendment raises shares available for awards by 3,550,000; approved with 68,005,433 votes for and 1,269,231 against.
- PricewaterhouseCoopers LLP ratified as independent auditor for fiscal 2026 with 72,313,820 votes for and 863,179 against.
- Advisory say-on-pay proposal approved with 68,472,769 votes for and 732,580 against.
The filing
Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 08, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.